凝血和瘤系统通过蛋白质溶解和通过血栓激素激活表皮生长因子受体直接联系在一起
Tianfa Wang1, Zhiyuan Shen1, Liu Yang1
1Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Oncogene
|February 5, 2025
概括
凝血素通过分裂EGFR促进肺癌的进展和化学疗法耐药性,激活关键信号通路. 用抑制剂阻断血素为肺腺癌 (LUAD) 提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 癌症缓解症和血栓形成是癌症晚期致命的.
- 凝血素,一个关键的凝血酶,与瘤进展有未知的直接联系.
- 肺腺癌 (LUAD) 患者的结果和化疗反应需要改进治疗点.
研究的目的:
- 研究血栓在肺腺癌 (LUAD) 进展和化疗耐药性中的作用.
- 阐明血栓介导瘤生长和治疗失败的机制.
- 评估血栓抑制作为LUAD的治疗策略.
主要方法:
- 对TCGA和临床病理数据的分析,用于LUAD中的血栓激素表达.
- 在体外和体内研究使用遗传学和药理学方法来评估血栓素的作用.
- 研究血素对表皮生长因子受体 (EGFR) 裂变和下游信号通路 (EGFR/AKT/mTOR) 的影响.
- 使用血栓激素抑制剂和化疗的组合治疗的评估.
主要成果:
- 在LUAD中的血栓激素表达与临床病理特征,预后和化疗结果相关.
- 血的催化活性直接驱动肺癌的进展在体外和体内.
- 凝血素将EGFR切割到一个保存的动机,激活EGFR/AKT/mTOR通路.
- 与化疗相结合的血栓激素抑制显示出增强的抗瘤疗效,克服了耐药性.
结论:
- 血栓素在通过EGFR分裂的LUAD进展和化疗耐药性中发挥着关键作用.
- 血栓素是肺癌的潜在预后生物标志物.
- 阻断血栓活性是一种可行的治疗策略,可以改善LUAD治疗结果并克服化疗耐药性.
相关概念视频
01:20Extrinsic and Intrinsic Pathways of Hemostasis
5.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.0K
01:17Intracellular Signaling Affects Focal Adhesions
2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.5K
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
01:16Clot Retraction and Fibrinolysis
3.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.6K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:09Coagulation
4.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.3K